Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769693 | 0.75 | ADORA2A (0.46) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL22229603 | 0.75 | GRM4 (0.41) | — | |
| Hydrochloric Acid SCHEMBL20769744 | 0.70 | CD38 (0.38) | CD38 | |
| SCHEMBL20769711 | 0.60 | ROCK2 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL1271374 | 0.60 | — | — | |
| SCHEMBL1991785 | 0.59 | JAK2 (0.44) | — | |
| SCHEMBL25253170 | 0.59 | JMJD6 (0.49) | KMT2A | |
| SCHEMBL31277599 | 0.59 | JMJD6 (0.49) | KMT2A | |
| SCHEMBL27620339 | 0.59 | MAPT (0.42) | MEN1NPC1RAB9AKMT2AKMO | |
| SCHEMBL4028475 | 0.58 | KDM4E (0.59) | NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2020-07-23 | — | — | US | disclosed |
| EP-3676262-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046795-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, RHOT2 | MEN1 2098/4885NPC1 2508/4885RAB9A 1044/4885 |
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ROCK1, ROCK2, RHOT2 | MEN1 2098/4885NPC1 2508/4885RAB9A 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.